Last reviewed · How we verify
Recombinant Human Thrombin
At a glance
| Generic name | Recombinant Human Thrombin |
|---|---|
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ovarian Hyperstimulation and Fibrin Clot Properties. (NA)
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants (PHASE1)
- Evaluating Postoperative Non-Opioid Pain Management Utilizing Local Anesthetics Coupled With Modulated Coagulation (PHASE4)
- Islet Transplant Alone in OMENtum (PHASE2)
- Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis (PHASE3)
- Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults (PHASE1)
- Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |